Review

January 22, 2025


Unveiling the intratumor microbiome in liver cancer: Current insights and prospective applications
Xindi Ke, Shangze Jiang, Qiaoxin Wei, et al.
Clin Mol Hepatol. 2025;31(3):685-705.

Review

February 5, 2025


Deciphering adenosine signaling in hepatocellular carcinoma: Pathways, prognostic models, and therapeutic implications
Huihai Yang, Martina Mang Leng Lei, Longfei Xie, et al.
Clin Mol Hepatol. 2025;31(3):706-729.

Review

March 26, 2025


Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrum
Vishnu Girish, Rakhi Maiwall
Clin Mol Hepatol. 2025;31(3):730-752.

Review

April 2, 2025


Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment
Hee Yeon Kim, Mary E. Rinella
Clin Mol Hepatol. 2025;31(3):753-770.

Review

April 16, 2025


Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease
Eiji Kakazu, Masaaki Mino, Tatsuya Kanto
Clin Mol Hepatol. 2025;31(3):771-795.

Original Article

January 6, 2025


High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease
Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, et al.
Clin Mol Hepatol. 2025;31(3):796-809.

Original Article

January 17, 2025


Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, et al.
Clin Mol Hepatol. 2025;31(3):810-822.

Original Article

January 22, 2025


Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition subsequent to hepatic fibrosis
Jae Yeon Kim, Hyeri Park, Soo Young Park, et al.
Clin Mol Hepatol. 2025;31(3):823-840.

Original Article

February 5, 2025


Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalently closed circular DNA minichromosome
Sheng-Tao Cheng, Wei-Xian Chen, Hai-Jun Deng, et al.
Clin Mol Hepatol. 2025;31(3):841-865.

Original Article

February 5, 2025


Baveno VI-SSM stratifies the risk of portal hypertensionrelated events in patients with HBV-related cirrhosis
Haiyu Wang, Weihao Liang, Ling Zhou, et al.
Clin Mol Hepatol. 2025;31(3):866-880.

Original Article

February 5, 2025


Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study
Bingtian Dong, Ruiling He, Shenghong Ju, et al.
Clin Mol Hepatol. 2025;31(3):881-898.

Original Article

February 5, 2025


Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study
Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Clin Mol Hepatol. 2025;31(3):899-913.

Original Article

February 6, 2025


GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma
Hyung Seok Kim, Jung Hwan Yoon, Ji Yi Choi, et al.
Clin Mol Hepatol. 2025;31(3):914-934.

Original Article

February 10, 2025


Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Gu-Wei Ji, Zheng-Gang Xu, Shuo-Chen Liu, et al.
Clin Mol Hepatol. 2025;31(3):935-959.

Original Article

March 4, 2025


CD36 promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in earlystage hepatocellular carcinoma
Yifei Qin, Fei Huo, Zhuan Feng, et al.
Clin Mol Hepatol. 2025;31(3):960-980.

Original Article

March 11, 2025


Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway
Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, et al.
Clin Mol Hepatol. 2025;31(3):981-1002.

Original Article

March 17, 2025


Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues
Rui Huang, Dae Won Jun, Hidenori Toyoda, et al.
Clin Mol Hepatol. 2025;31(3):1003-1017.

Original Article

April 4, 2025


Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
Hye Won Lee, Jae Seung Lee, Mi Na Kim, et al.
Clin Mol Hepatol. 2025;31(3):1018-1031.

Original Article

April 11, 2025


MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation
Tiantian Wang, Dean Rao, Chenan Fu, et al.
Clin Mol Hepatol. 2025;31(3):1032-1057.

Original Article

April 11, 2025


Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States
Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, et al.
Clin Mol Hepatol. 2025;31(3):1058-1070.

Original Article

April 21, 2025


HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
Vincent Wai-Sun Wong, Guy W. Neff, Adrian M. Di Bisceglie, et al.
Clin Mol Hepatol. 2025;31(3):1071-1083.

Original Article

April 23, 2025


Glucagon-like peptide 1 receptor agonist and reduced liver and non-liver complications in adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: a target trial emulation study
Xianhua Mao, Xinrong Zhang, Rongtao Lai, et al.
Clin Mol Hepatol. 2025;31(3):1084-1099.


Articles in E-pub version are posted online ahead of regular printed publication.

Correspondence
Response to Editorial on Ciociola et al., "Downregulation of the MARC1 p.A165 Risk Allele Reduces Hepatocyte Lipid Content by Increasing Beta-Oxidation"
Ester Ciociola, Tanmoy Dutta, Rosellina M. Mancina, Stefano Romeo
Received July 11, 2025  Accepted July 11, 2025  
View: 58   Download: 4
Correspondence to “Critical Flaws in the Molecular Classification of HCC Based on Metabolic Zonation”
Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo
Received July 10, 2025  Accepted July 11, 2025  
View: 62   Download: 9
Editorial
Editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program”: Redefining MTCT prevention strategies toward HBV elimination
Eunho Choi, Ji Hoon Kim, Young-Sun Lee
Received July 8, 2025  Accepted July 11, 2025  
View: 71   Download: 4
Clinical implications of residual changes following HCV clearance
So-Young Kim, Eui-Cheol Shin
Received July 3, 2025  Accepted July 11, 2025  
View: 55   Download: 5
Letter to the Editor
Letter to the editor on” Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial. ”
Bitao Jiang, Song Zhang, Lingling Bao
Received June 28, 2025  Accepted July 10, 2025  
View: 88   Download: 12
Reconsidering the Role of Plasma pgRNA in NUC-treated CHB: Stratified Biomarker Interpretation and the Limits of Current Assays
Xu Han, Jun Sun, Yinyan Li
Received June 16, 2025  Accepted July 6, 2025  
View: 98   Download: 11
Correspondence
Correspondence to editorial on “GLP-1RA may open a new era for MASLD treatment”
Xianhua Mao, Mindie H Nguyen
Received June 29, 2025  Accepted July 2, 2025  
View: 114   Download: 9
Reply: Early Cancer Risk Reduction After GLP-1RA Use: Signal or Bias?
Xianhua Mao, Mindie H Nguyen
Received June 29, 2025  Accepted July 3, 2025  
View: 77   Download: 4
Editorial
The other face of GWAS: Editorial on “Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of MASLD”
Hyungtai Sim, Murim Choi
Received June 22, 2025  Accepted July 2, 2025  
View: 94   Download: 6
Original Article
Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation
Changze Hong, Zuxiong Huang, Yingli He, Rongqi Wang, Jiaying Lin, Yushan Liu, Baicheng Liu, Xiaoqin Lan, Qinjun He, Wenfan Luo, Qintao Lai, Ling Zhou, Tingting Qi, Yali Ji, Miaoxia Liu, Qiaoping Wu, Yichen Yao, Weihao Liang, Xianbo Wang, Guohong Deng, Yanhang Gao, Yan Huang, Feng Liu, Xiaobo Lu, Zhongji Meng, Yuemin Nan, Hai Li, Beiling Li, Rajiv Jalan, Jinjun Chen
Received March 25, 2025  Accepted July 1, 2025  
View: 333   Download: 26
Letter to the Editor
Letter"Novel Genetic Modulators of MASLD Identified Through Genome-Wide Interaction with BMI"
Sheng Zheng
Received June 18, 2025  Accepted June 26, 2025  
View: 167   Download: 12
Correspondence
Correspondence to letter to the editor on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”
Hye Won Lee, Seung Up Kim
Received June 17, 2025  Accepted June 20, 2025  
View: 165   Download: 10
Editorial
GLP-1RA may open a new era for MASLD treatment
Ye Feng, Chengfu Xu
Received June 12, 2025  Accepted June 19, 2025  
View: 266   Download: 36
Letter to the Editor
Critical Flaws in the Molecular Classification of HCC Based on Metabolic Zonation
Yongzhi Xie, Xiangyu Zhu, Qi Liang
Received June 9, 2025  Accepted June 20, 2025  
View: 174   Download: 20
Review
Update in the Treatment of Cirrhotic Patients with Portal Vein Thrombosis
Jialin Wu, Xinyi Deng, Junyang Luo, Zaibo Jiang, Fuda Xie, Bonan Chen, Hoi Wing Leung, Ge Zhang, Ka Fai To, Wei Kang
Received April 12, 2025  Accepted June 19, 2025  
View: 482   Download: 118
Original Article
Factors associated with hepatitis B mother-to-child transmission in a national prevention program
Moran Ki, Byung-Woo Kim, Dahye Baik, Jong-Hyun Kim
Received February 24, 2025  Accepted June 20, 2025  
View: 308   Download: 50
Reply to Correspondence
Correspondence on “Reply to "Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers"”
Dibin Liu
Received June 8, 2025  Accepted June 13, 2025  
View: 197   Download: 21
Correspondence
Reply to the letter to the editor on “Re: “Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States”
Pojsakorn Danpanichkul, Luis Antonio Diaz, Juan Pablo Arab, Amit G. Singal, Ju Dong Yang
Received June 5, 2025  Accepted June 13, 2025  
View: 262   Download: 9
Reply to the letter:Advancing the Baveno VI-SSM Model for Clinical Utility in HBV-Related Cirrhosis
Haiyu Wang, Jinjun Chen
Received June 9, 2025  Accepted June 10, 2025  
View: 186   Download: 2
Original Article
Non-contrast MRI for Detection of Late Recurrent Hepatocellular Carcinoma After Curative Treatment: A Prospective Multicenter Comparison to Contrast-enhanced CT
Dong Wook Kim, Won Chang, So Yeon Kim, Young-Suk Lim, Jonggi Choi, Jungheum Cho, Jin-Wook Kim, Jai Young Cho, Sun Kyung Jeon, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Kyung-Suk Suh, Kwang-Woong Lee, Dong Ho Lee
Received March 4, 2025  Accepted June 10, 2025  
View: 477   Download: 60
Letter to the Editor
Letter “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
Jun Sun, Xu Han, Yinyan Li
Received June 2, 2025  Accepted June 4, 2025  
View: 247   Download: 20
Re: “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
Bitao Jiang, Lingling Bao
Received June 1, 2025  Accepted June 4, 2025  
View: 236   Download: 24
Early Cancer Risk Reduction After GLP-1RA Use: Signal or Bias?”
Shio-Shin Jean, Chih-Cheng Lai
Received May 31, 2025  Accepted June 4, 2025  
View: 201   Download: 22
Review
Prospects of Mendelian Randomization in Hepatology: A Comprehensive Literature Review with Practice Guidance Mendelian randomization and hepatology
Lanlan Chen, Qi Rao, Menghan Gao, Guoyue Lv, Frank Tacke
Received May 16, 2025  Accepted June 3, 2025  
View: 867   Download: 95
Letter to the Editor
Letter "Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease"
Chunyan Wang, Jun Sun, Yinyan Li
Received May 16, 2025  Accepted June 5, 2025  
View: 252   Download: 15
Reply to Correspondence
Reply to correspondence on “Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B”
Heejoon Jang, Won Kim
Received May 14, 2025  Accepted June 4, 2025  
View: 452   Download: 2
Reply to correspondence on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
Received May 26, 2025  Accepted May 30, 2025  
View: 332   Download: 12
Letter to the Editor
Letter “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Bo Zheng, Lizhou Wang
Received May 11, 2025  Accepted May 31, 2025  
View: 218   Download: 20
Original Article
Distinct Inflammatory Imprint in Non-Cirrhotic and Cirrhotic Patients Before and After Direct-Acting Antiviral Therapy
Moana Witte, Carlos Oltmanns, Jan Tauwaldt, Hagen Schmaus, Jasmin Mischke, Gordon Grabert, Mara Bretthauer, Lennart M. Roesner, Thomas Werfel, Katja Deterding, Benjamin Maasoumy, Heiner Wedemeyer, Tim Kacprowski, Anke R.M. Kraft, Markus Cornberg
Received March 20, 2025  Accepted June 2, 2025  
View: 531   Download: 48
Reply to Correspondence
Reply to correspondence on “Unveiling TRIB3: A New Mediator in MET-Driven Hepatocellular Carcinoma Progression
Many Sze Man Chan, Terence Kin Wah Lee
Received May 14, 2025  Accepted May 30, 2025  
View: 266   Download: 7
Original Article
Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of MASLD
Oveis Jamialahmadi, Endrina Mujica, Lowri Morris, Rosellina Margherita Mancina, Ester Ciociola, Sami F. Qadri, Samantha Maurotti, Francesco Malvestiti, Ruifang Li-Gao, Luisa Ronzoni, Federica Tavaglione, Hannah Maude, Amin Allalou, Anastasia Emmanouilidou, Umberto Vespasiani-Gentilucci, Frits Richard Rosendaal, Hannele Yki-Järvinen, Inês Cebola, Luca Valenti, Marcel den Hoed, Stefano Romeo
Received February 26, 2025  Accepted May 29, 2025  
View: 853   Download: 97
Letter to the Editor
Re: “Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States”
Dibin Liu
Received May 15, 2025  Accepted May 23, 2025  
View: 192   Download: 17
Correspondence
Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications”
Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
Received May 13, 2025  Accepted May 14, 2025  
View: 387   Download: 7
Correspondence: Response to Editorial on “Uncovering the MET-TRIB3-FOXO1 axis: A Novel Target in MET-driven Hepatocellular Carcinoma”
Tiantian Wang, Wenjie Huang, Limin Xia
Received May 11, 2025  Accepted May 14, 2025  
View: 404   Download: 12
Editorial
Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications
Sung-Eun Kim
Received May 9, 2025  Accepted May 13, 2025  
View: 246   Download: 11
Uncovering the MET-TRIB3-FOXO1 axis: A Novel Target in MET-driven Hepatocellular Carcinoma
Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
Received May 9, 2025  Accepted May 13, 2025  
View: 513   Download: 45
Correspondence
Correspondence: Response to Editorial on “Unveiling TRIB3: A New Mediator in MET-Driven Hepatocellular Carcinoma Progression”
Tiantian Wang, Wenjie Huang, Limin Xia
Received May 6, 2025  Accepted May 8, 2025  
View: 349   Download: 16
Reply to Correspondence
Advancing Metabolic Risk Profiling in Chronic Hepatitis B
Shang-Chin Huang, Jia-Horng Kao
Received May 4, 2025  Accepted May 8, 2025  
View: 249   Download: 12
Correspondence
Correspondence to editorial “Metabolic health in antiviral era of chronic hepatitis B”
Rui Huang, Mindie H. Nguyen
Received April 29, 2025  Accepted May 4, 2025  
View: 298   Download: 3
Correspondence to letter to the editor on “Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease: The KASL Pathway
Hye Won Lee, Seung Up Kim
Received April 29, 2025  Accepted May 3, 2025  
View: 274   Download: 4
Letter to the Editor
Molecular Stratification of Hepatocellular Carcinoma by Metabolic-Signaling Pathways Guides Precision Immunotherapy and TACE Therapy
Binghua Li, Yanchao Xu, Yican Zhu, Yukun Zhang, Zijie Wu, Tianci Luo, Laizhu Zhang, Weiwei Hu, Decai Yu
Received March 27, 2025  Accepted April 29, 2025  
View: 488   Download: 66  Crossref: 2
Editorial
Unveiling TRIB3: A New Mediator in MET-Driven Hepatocellular Carcinoma Progression
Many Sze Man CHAN, Terence Kin Wah LEE
Received April 23, 2025  Accepted April 24, 2025  
View: 397   Download: 31
Correspondence
Correspondence to editorial on “Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway.”
Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo
Received April 18, 2025  Accepted April 24, 2025  
View: 307   Download: 14
Editorial
Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B
Heejoon Jang, Won Kim
Received April 16, 2025  Accepted April 25, 2025  
View: 639   Download: 18
RISK STRATIFICATION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: THE KASL PATHWAY
May Xuan GOH, Xin En GOH, Jarell Jie-Rae TAN, Vincent L CHEN, Yu Jun WONG
Received April 14, 2025  Accepted April 24, 2025  
View: 289   Download: 19
Reply to Correspondence
GULP1: New Hope for Hepatocellular Carcinoma: Reply to Correspondence on “GULP1 as a Novel Biomarker in HCC”
Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen
Received April 14, 2025  Accepted April 24, 2025  
View: 318   Download: 16
Correspondence
Correspondence to editorial “Targeting CD36 to reinvigorate CD8+ T Cells in early-stage hepatocellular carcinoma”
Yifei Qin, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu
Received April 11, 2025  Accepted April 24, 2025  
View: 1294   Download: 25
Letter to the Editor
Letter “Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target”
Yuqian Liu, Ruiyun Guo, Jun Ma
Received April 6, 2025  Accepted April 21, 2025  
View: 371   Download: 41
Reply to Correspondence
Reply to authors’ reply: “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Mathias Jachs, Mattias Mandorfer
Received April 9, 2025  Accepted April 14, 2025  
View: 361   Download: 11
Correspondence
Correspondence to Editorial on “Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial”
Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
Received April 7, 2025  Accepted April 8, 2025  
View: 325   Download: 16
Editorial
Metabolic Health in Antiviral Era of Chronic Hepatitis B
Shang-Chin Huang, Jia-Horng Kao
Received April 3, 2025  Accepted April 8, 2025  
View: 382   Download: 23
Correspondence
Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients
Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu
Received April 2, 2025  Accepted April 2, 2025  
View: 549   Download: 15
Correspondence: Response to Editorial on “GULP1, a Multifaceted Biomarker and Therapeutic Target in HCC”
Soon Sun Kim, Hyung Seok Kim, Jae Youn Cheong, Jung Woo Eun
Received March 28, 2025  Accepted April 2, 2025  
View: 368   Download: 11
Editorial
Targeting CD36 to reinvigorate CD8+ T Cells in early-stage hepatocellular carcinoma
Valerie Chew
Received March 25, 2025  Accepted March 28, 2025  
View: 573   Download: 46
Correspondence
Correspondence to editorial 3 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Haiyu Wang, Jinjun Chen
Received March 23, 2025  Accepted March 28, 2025  
View: 381   Download: 7
Correspondence to editorial 2 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Haiyu Wang, Jinjun Chen
Received March 23, 2025  Accepted March 28, 2025  
View: 411   Download: 6
Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
Haiyu Wang, Jinjun Chen
Received March 23, 2025  Accepted March 28, 2025  
View: 406   Download: 13
Editorial
GULP1, A Multifaceted Diagnostic Biomarker and Potential Therapeutic Target in Hepatocellular Carcinoma: Editorial on “GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma”
Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen
Received March 18, 2025  Accepted March 21, 2025  
View: 494   Download: 32
Besifovir: a viable option for long-term disease control in chronic hepatitis B
Wai-Kay Seto
Received March 15, 2025  Accepted March 20, 2025  
View: 324   Download: 18
Refining Portal Hypertension Assessment: The Clinical Significance of Spleen Stiffness Measurement in the Baveno VII Era
Do Seon Song
Received March 13, 2025  Accepted March 20, 2025  
View: 377   Download: 35
Letter to the Editor
Letter “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Qiong Wang, Zhongqing Qian, Xiaodi Yang, Deyan Chen, Xiaojing Wang, Fuliang Chen
Received March 13, 2025  Accepted March 19, 2025  
View: 392   Download: 22
Correspondence
Correspondence: Response to the Letter Regarding "GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma"
Hyung Seok Kim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
Received March 12, 2025  Accepted March 15, 2025  
View: 530   Download: 27
Editorial
Unveiling GULP1 as a Hepatocyte-Specific Role for Recurrence: Editorial on “GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma”
Pengde Lu, Ning Wang
Received March 11, 2025  Accepted March 15, 2025  
View: 503   Download: 25
A non-invasive risk stratification tool for hepatitis B-related liver cirrhosis: the Baveno VI-SSM combined model.
Ruiling He, Bingtian Dong, Xiaolong Qi
Received March 11, 2025  Accepted March 15, 2025  
View: 571   Download: 38
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?
Mathias Jachs, Mattias Mandorfer
Received March 11, 2025  Accepted March 15, 2025  
View: 450   Download: 28
Letter to the Editor
Critical Considerations in Evaluating the Therapeutic Potential of HK-660S for Primary Sclerosing Cholangitis
He Yizi, He Haifeng, Liang Qi, Xie Yongzhi
Received March 1, 2025  Accepted March 13, 2025  
View: 401   Download: 32
Reply to Correspondence
SHOULD DIRECT-ACTING ANTIVIRAL BE CONSIDERED FOR ALL PATIENTS WITH HCV-RELATED HEPATOCELLULAR CARCINOMA?
Yan Ling ONG, Apichat KAEWDECH, Yu Jun WONG
Received March 5, 2025  Accepted March 10, 2025  
View: 417   Download: 13
Regulation of Hepatitis B Virus cccDNA by Metabolic Pathways
Hyeong-Jin Cho, Sung-Gyoo Park
Received March 4, 2025  Accepted March 9, 2025  
View: 611   Download: 58  Crossref: 1
Letter to the Editor
Letter “GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma”
Juan Yang, Xinyi Li, Sheng Zheng
Received February 24, 2025  Accepted March 5, 2025  
View: 536   Download: 54
Letter to the Editor on “Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023”
Sisi Yang, Zhenxuan Ma
Received February 11, 2025  Accepted March 6, 2025  
View: 455   Download: 23
Correspondence
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage
Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu
Received February 28, 2025  Accepted March 1, 2025  
View: 659   Download: 23
HCC predictors in routine practice for patients with chronic liver diseases
Tung-Hung Su, Jia-Horng Kao
Received February 18, 2025  Accepted February 22, 2025  
View: 372   Download: 11
Editorial
Direct-acting antiviral attained sustained virological response improve overall survival in patients with HCV-related hepatocellular carcinoma
Yan Ling Ong, Apichat Kaewdech, Daniel Q Huang, Yu Jun Wong
Received February 14, 2025  Accepted February 21, 2025  
View: 602   Download: 32
Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease
Ho Soo Chun, Minjong Lee
Received February 2, 2025  Accepted February 7, 2025  
View: 559   Download: 21
Original Article
Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in acute liver failure
Neha Sharma, Sushmita Pandey, Gaurav Tripathi, Manisha Yadav, Nupur Sharma, Babu Mathew, Abhishak Gupta, Vasundhra Bindal, Sadam H. Bhat, Yash magar, Rimsha Saif, Sanju Yadav, Amritpal Kaur, Rakhi Maiwall, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras
Received July 12, 2024  Accepted December 10, 2024  
View: 5759   Download: 148

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 2103
TOTAL : 2953959
Close layer